Clinical improvement (dichotomous) · active EoE patients
Biologics showed no clear difference in clinical improvement (dichotomous) compared with placebo (low certainty).
1 finding from 1 review
Clinical improvement (continuous) · active EoE patients
1 finding from 1 review
Histological improvement (dichotomous) · active EoE patients
Biologics probably leads to higher histological improvement (dichotomous) compared with placebo (moderate certainty).
1 finding from 1 review
Histological improvement (continuous) · active EoE patients
1 finding from 1 review
Endoscopic improvement (dichotomous) · active EoE patients
1 finding from 1 review
Endoscopic improvement (continuous) · active EoE patients
1 finding from 1 review
Withdrawals due to adverse events · active EoE patients
Biologics showed no clear difference in withdrawals due to adverse events 12 to 44 weeks compared with placebo (low certainty).
1 finding from 1 review
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
Summary of findings table ‐ Subcutaneous biologics (dupilumab) showed no clear difference in short‐term hair regrowth ≥ 75% compared with placebo (low certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
Summary of findings table ‐ Subcutaneous biologics (dupilumab) showed no clear difference in incidence of serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Health‐related quality of life ‐ not reported · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Eating a normally varied diet · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions
The review found no eligible studies for this question.
1 finding from 1 review
Restoration of sexual activity · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions
The review found no eligible studies for this question.
1 finding from 1 review
Reduction in number of flares · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions
The review found no eligible studies for this question.
1 finding from 1 review
Reduction in severity of flares · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions
The review found no eligible studies for this question.
1 finding from 1 review
Disease‐specific quality of life · patients with severe chronic rhinosinusitis with nasal polyps
1 finding from 1 review
Disease severity ‐ VAS (range 0 to 10, lower = better) · patients with severe chronic rhinosinusitis with nasal polyps
1 finding from 1 review
Serious adverse events · patients with severe chronic rhinosinusitis with nasal polyps
It is very uncertain whether anti‐IL‐5 mAb (mepolizumab) changes serious adverse events compared with placebo (on top of topical steroids) (very low certainty).
1 finding from 1 review
Avoidance of surgery ‐ patients still meeting the criteria for surgery At end of · patients with severe chronic rhinosinusitis with nasal polyps
It is very uncertain whether anti‐IL‐5 mAb (mepolizumab) changes avoidance of surgery ‐ patients still meeting the criteria for… compared with placebo (on top of topical steroids) (very low certainty).
1 finding from 1 review
Extent of disease ‐ endoscopic score · patients with severe chronic rhinosinusitis with nasal polyps
1 finding from 1 review